RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT)
Heart surgery involving valve replacement often involves the use of the heart-lung machine for over 90 minutes, and bleeding tendency is frequently seen. Conventionally, platelet transfusion has been the primary therapy to treat bleeding after this type of procedure. More recently, perioperative supplementation of purified fibrinogen (RiaSTAP, CSL Behring) was shown to reduce bleeding and blood product use (plasma or platelets) after heart surgery. The objective of this trial is to demonstrate the clinical equivalency and economic utility of using fibrinogen concentrate, RiaSTAP for the mitigation of post-operative bleeding in patients in lieu of platelet transfusion.
Purified fibrinogen concentrate has been approved by FDA, and it has been used for the treatment of acute bleeding episodes in patients with low fibrinogen due to hereditary causes (e.g., afibrinogenemia). Compared to the transfusion of platelets which may be associated with volume overload, bacterial/viral infection, immunological effects and excess blood clotting, purified fibrinogen has several advantages. First, it contains no liquid plasma allowing for low volume infusion. Several viral inactivation/reduction steps are used to prepare the fibrinogen concentrate, increasing its viral safety. No antibodies or white blood cells are contained in the fibrinogen concentrate; therefore transfusion reactions are rare. Although platelet transfusion is widely used after heart surgery, there has been no randomized study to endorse this practice. In this study, patients undergoing heart valve replacement will be randomized to receive either platelet (1 unit) transfusion or fibrinogen concentrate (4g) after heparin anticoagulation is reversed. Subjects will be treated only if there is evidence of significant microvascular bleeding. Fifteen minutes after the initial treatment, subjects will be reevaluated for bleeding. If bleeding continues, subjects will be treated with blood transfusion per institutional standard of care.
The primary endpoints for this study are the hemostatic condition of the surgical field and 24-hour total of blood product transfusion.
|Heart Valve Disease Coronary Artery Disease||Drug: Human fibrinogen concentrate Other: apheresis platelets||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||RiaSTAP vs. Conventional Transfusion for Patients Undergoing Valve Replacement Surgery: RiaCT|
- Bleeding Scores [ Time Frame: intra-operatively and up to 24 hours postoperatively ]Bleeding scores are scored on a four-point scale. A visual assessment of surgical field was performed by the senior surgical staff as follows: 0 = excellent hemostasis (dry field), 1 = mild bleeding (oozing), 2 = moderate bleeding (controllable with applied pressure), and 3 = severe bleeding (multiple diffuse bleeding sites). If the visual bleeding scale was 2 to 3, the subjects were randomly assigned to a study intervention using a closed envelope method.
- Proportion of Patients in the Fibrinogen Group in Whom Transfusion of Fresh Frozen Plasma or Platelet Concentrate is Required During or After Surgery [ Time Frame: Operative period ]
- Units of Fresh-frozen Plasma (FFP) Transfused-during Surgery and up to 24 Hours After Surgery [ Time Frame: Peri-operative period ]
- Units of Platelets and Allogeneic Red Cells Transfused- During Surgery and up to 24 Hours After Surgery [ Time Frame: Peri-operative period ]
- Blood Loss [ Time Frame: Operative period ]
|Study Start Date:||January 2011|
|Study Completion Date:||May 2013|
|Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Experimental: Group A: RiaSTAP
Human fibrinogen concentrate
Drug: Human fibrinogen concentrate
4 g IV once, within 30 minutes of ACT < 155 seconds, post CPB, with evidence of significant microvascular bleeding
Other Name: RiaSTAP
Active Comparator: Group B: apheresis platelets
single apheresis unit
Other: apheresis platelets
A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT <155 seconds post CPB with evidence of significant microvascular bleeding.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01283321
|United States, Georgia|
|Emory University Hospital|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Gautam Sreeram, MD||Emory University|
|Principal Investigator:||Kenichi Tanaka, MD, MSc||University of Maryland|